+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID05633654

Randomized Study Comparing Sacituzumab Govitecan and Pembrolizumab to Physicians Choice Treatment for Triple Negative Breast Cancer After Surgery and Neoadjuvant Therapy

Led by Gilead Sciences · Updated on 2026-11-04

1514

Participants Needed

378

Research Sites

217 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of sacituzumab govitecan-hziy SG combined with pembrolizumab compared to treatment chosen by a physician for people with triple negative breast cancer that remains after surgery and pre-surgical treatment. This phase 3 trial focuses on participants whose cancer has not been fully eliminated by prior therapies and aims to find if the experimental combination improves invasive disease-free survival. Participants are randomly assigned to one of two groups. One group receives SG intravenously at 10 mgkg on Days 1 and 8 of each 21-day cycle plus pembrolizumab 200 mg intravenously on Day 1 of each cycle for up to 8 cycles. The other group receives either pembrolizumab alone or pembrolizumab plus oral capecitabine as determined before randomization, also for up to 8 cycles. Treatment continues until reaching 8 cycles, disease recurrence, unacceptable side effects, physician decision, consent withdrawal, or death. During the study, participants undergo various evaluations including monitoring for invasive disease-free survival for up to 60 months and overall survival for up to 96 months. Researchers also track recurrence-free survival, distant disease-free survival, treatment side effects, laboratory abnormalities, and quality of life changes. Safety assessments occur up to 38 months after the first dose plus 30 days. This long-term follow-up helps understand the treatments impact over several years.

CONDITIONS

Brief Title

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Research Team

G

Gilead Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here